BioCentury This Week

BioCentury This Week

BioCentury
Country USA
Language EN-US
Episodes 390
Latest 16.11.2026

BioCentury's streaming commentary on biotech industry trends, plus interviews with key opinion leaders. The show draws on three decades of BioCentury's expertise in helping biopharma executives and investors make business-critical decisions. It covers developments across the innovation ecosystem, offering insights for professionals in the sector.

Episodes

  • Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds
    Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds 16.11.2026 28m
    J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular edema. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the terms of the deal, what it says about NewCos as an exit path and Blackstone Life Sciences’ role in funding Phase III. The analysts also assess how a growing neoantigen vaccine pipeline is testing the modality’s reach after Merck and...
  • Ep. 397 - What the U.S. midterms mean for biopharma
    Ep. 397 - What the U.S. midterms mean for biopharma 09.11.2026 28m
    Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing legislation. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the results mean for FDA and HHS leadership, user fee negotiations, vaccine regulation, and the prospect of applying most-favored nation pricing to Medicare drug price negotiation. The analysts also unpack full Phase III data showing pelac...
  • Ep. 396 - China’s first-order innovation
    Ep. 396 - China’s first-order innovation 06.11.2026 29m
    Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special edition of the BioCentury This Week podcast recorded live at the 13th BioCentury-BayHelix China Healthcare Summit in Shanghai, BioCentury’s Jeff Cranmer, Simone Fishburn and Josh Berlin are joined by Kali Therapeutics CEO Weihao Xu, Charles River’s Matthew Hewitt and Aerska CEO Jack O’Meara to discuss key themes from...
  • Ep. 395 - ESMO analysis & Auchincloss proposal
    Ep. 395 - ESMO analysis & Auchincloss proposal 02.11.2026 33m
    A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why new targets alone may not be enough to overcome resistance. Turning to policy, the analysts examine Representative Jake Auchincloss’ Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us bioban...
  • Ep. 394 - Security concerns in U.S., China reshaping biotech
    Ep. 394 - Security concerns in U.S., China reshaping biotech 26.10.2026 33m
    Proposed U.S. Treasury rules implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotechs, potentially ensnaring Asia-to-West NewCos while leaving licensing intact. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the rule’s implications for cross-border dealmaking, the competitive opening it may create for European companies, and China’s narrower-than-feared draft export controls on platform technologies. Th...
  • Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
    Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau 19.10.2026 30m
    Roche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets. On the latest BioCentury This Week podcast, BioCentury’s analysts assess trends to watch ahead of Shanghai Life Sciences Week, including how new rules have curtailed China’s IIT pathway and a proposed export-control regime that could complicate cell and gene therapy and siRNA deals. The analysts also discuss Merck KGaA’...
  • Ep. 392 - Biotech markets: Pause before the storm?
    Ep. 392 - Biotech markets: Pause before the storm? 12.10.2026 24m
    An M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling some quality names and follow-on activity slowed. On the latest BioCentury This Week podcast, BioCentury’s analysts preview the fourth quarter, where rising bond yields and the U.S. midterms could keep financing and deal activity quiet through year-end. The analysts also discuss why late-stage misses in Lp(a), IL-6, and Factor XI are pushing de...
  • Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
    Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners 05.10.2026 30m
    Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the preceden...
  • Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
    Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways 30.09.2026 34m
    Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a special live edition of the BioCentury This Week podcast, BioGeneration Ventures' Oskar Slotboom, NautaDutilh's Ruud Smits and Leyden Labs' Dinko Valerio join BioCentury's analysts to discuss women's health and sleep as lenses on disease, and the shift toward prevention. The panel also weighs the limits of "Frankenstei...
  • Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
    Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look 28.09.2026 37m
    Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen, Novartis, Takeda, Climb Bio and Jade chasing targets such as APRIL, BAFF and CD38. On the latest BioCentury This Week podcast, BioCentury's analysts assess how next-generation therapies are competing on safety and longer dosing intervals. The analysts also discuss Heidi Overton's FDA commissioner confirmation hearing and li...
  • Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
    Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs 21.09.2026 32m
    The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an alternate route to NASDAQ. On the latest BioCentury This Week podcast, BioCentury's analysts examine momentum in the biotech IPO market. The team also unpacks fatal toxicities in Novartis' autoimmune CAR-T trials and what they reveal about manufacturing, dosing and immune biology risks across the modality. In Washington, S...
  • Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
    Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs 14.09.2026 30m
    Note: This episode was briefly published with an incorrect audio file, which has since been corrected. FDA is prepared to approve psychedelic therapies for chronic psychiatric disorders before sponsors have fully determined how long the effects last or when patients should receive second or subsequent doses. On the latest BioCentury This Week podcast, BioCentury's analysts assess the latest guidance on psychedelics from FDA. The team also discusses takeaways from Michael Davis' first intervi...
  • Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
    Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs 08.09.2026 35m
    A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense oligonucleotide therapy pelacarsen. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the fallout for Lp(a) as a cardio target and whether issues with the target, modality or treatment setting contributed to the therapy's lack of efficacy. The analysts also review BioCentury's annual big pharma deals analysis...
  • Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
    Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton 31.08.2026 35m
    Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trade-offs companies face, the litigation risks around mandatory Medicare MFN pricing demonstrations, and what happens to companies that don't sign on. The analysts also discuss Eli Lilly's acquisition of Merida, its thirteenth takeout of the year, Heidi Overton's nomination as FDA commissio...
  • Ep. 384 - Back to School Special: The global FIH trials race
    Ep. 384 - Back to School Special: The global FIH trials race 27.08.2026 42m
    China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for complacency. On a special edition of the BioCentury This Week podcast, BioCentury's analysts discuss why transformational reform for early clinical development will require rethinking the risk-control paradigm for first-in-human trials. It’s the subject of the...
  • Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
    Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick 24.08.2026 19m
    A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the vaccine’s prospects and the broader implications. The analysts also discuss Roche/Genentech’s deal with Hanmi, which will add to the MNC’s obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that ha...
  • Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
    Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA 17.08.2026 25m
    A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the financings, which included money for a potential challenger to Amgen’s blockbuster Tepezza and a new venture from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio. The analysts also discuss new approaches to drug cancer’s “undruggable” β-catenin pathway, and whether Capricor’s...
  • Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
    Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs 10.08.2026 31m
    Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more efficiently. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how stakeholders in the U.S. are responding to the challenge. The analysts also discuss the next frontiers of federated learning in drug discovery and the latest crop of biotech IPOs on NASDAQ, which raised over $1.2B in strong IPO run last...
  • Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
    Ep. 380 - AZ-BMS rumors, Replimune, psychedelics 03.08.2026 32m
    Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it. The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression. View full story: https://www.biocentury.com/article/660376 #BiotechMA #FDA ...
  • Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
    Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard 27.07.2026 34m
    Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the strategy that has made autoimmune drug Vyvgart efgartigimod alfa a blockbuster. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the deal and put it in the context of a new cohort of large-cap companies increasingly active in biotech M&A. The analysts also assess how recent releases from Ant...

Popular in

The podcast also appears in the podcast charts of these countries.